Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

September 29, 2022

https://www.globenewswire.com/news-release/2022/09/29/2525106/0/en/Journal-of-Precision-Medicine-publication-confirms-GeneType-Risk-Test-outperforms-traditional-risk-assessments-for-breast-cancer.html

MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician.

Read more at globenewswire.com

Related news for (GENE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.